SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Blue Owl Capital, Inc. operates as an alternative asset management firm. It provides investors access to asset management capital solutions through its Direct Lending and GP Capital Solutions products. The company offers a platform of capital solutions to both middle market companies and large alternative asset managers. The company was founded by Doug Irving Ostrover, Michael Rees and Craig W.Packer in 2009 and is headquartered in New York, NY.

Blue Owl Capital Inc - Ordinary Shares - Class A

Blue Owl is drawing attention after a strong Q3 earnings report, with traders highlighting better-than-expected results, growth in assets and fee-related earnings, and managements positive outlook on dividend coverage and future fees. Many expect sentiment to improve, while others remain cautious about private-credit redemptions and point to put-heavy options activity.

NextDecade Corp. is a development company, which focuses on liquefied natural gas (LNG) export projects and associated pipelines. It develops and manages land-based and floating liquefied natural gas projects in the Gulf Coast with focus on the Rio Grande LNG. The company was founded by Kathleen Eishbrenner in 2010 and is headquartered in Houston, TX.

NextDecade Corporation

Discussion centers on speculation that Middle East LNG disruptions and shipping risks could strengthen demand and pricing for U.S. exporters, including NextDecades Rio Grande project. Bulls point to the projects progress and future capacity, while skeptics emphasize that NEXT has no current LNG production or revenue and still faces construction, financing, and competition risks.

Dogecoin (DOGE) is a cryptocurrency . Users are able to generate DOGE through the process of mining. Dogecoin has a current supply of 156,546,266,383.70521. The last known price of Dogecoin is 0.07588453 USD and is up 0.89 over the last 24 hours. It is currently trading on 1543 active market(s) with $1,129,852,058.92 traded over the last 24 hours. More information can be found at http://dogecoin.com/.

Dogecoin

Dogecoin is drawing attention for its choppy, weak trading and repeated difficulty holding above the eight-cent area, with traders also linking pressure to broader crypto-market declines. The conversation is split between bearish frustration over losses and calls to buy the dip or hold for a recovery.

Zebec Network (ZBCN) is a cryptocurrency launched in 2022and operates on the Solana platform. Zebec Network has a current supply of 99,998,768,617.445403. The last known price of Zebec Network is 0.00204055 USD and is down -0.09 over the last 24 hours. It is currently trading on 133 active market(s) with $10,537,951.06 traded over the last 24 hours. More information can be found at https://zebec.io/.

Zebec Network

Traders are focused on Zebecs payroll and payments expansion, including MoneyGram/Stellar links and Robinhood Chain support, as potential adoption drivers. Bullish holders are accumulating, while skeptics question whether actual usage will translate into ZBCN demand given its weak, uneven price performance.

Zoom Communications, Inc. engages in the provision of a communications and collaboration platform. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East, and Africa. The company was founded by Eric S. Yuan in 2011 and is headquartered in San Jose, CA.

Zoom Communications Inc. - Ordinary Shares - Class A

Zooms Anthropic investment is drawing attention amid IPO-filing and valuation chatter, with bullish traders viewing the stake as a potential source of value. Others question whether it can offset Zooms modest core-business growth and competitive pressures; discussion also references recent earnings beats and raised full-year guidance.

LightPath Technologies, Inc. engages in the design, development, manufacture, and distribution of optical and infrared components. Its products include molded glass and assemblies, infrared molded lenses, diamond turned, conventional ground and polished ground lenses and assemblies, and collimator assemblies, which are used in applications involving light detection and ranging technology. The firm supports a range of customers in the field of industrial, laser, defense, medical, telecommunications, and instrumentation. The company was founded in1985 and is headquartered in Orlando, FL.

Lightpath Technologies, Inc. - Ordinary Shares - Class A

LightPaths order for more than 50,000 optical assemblies for defense-drone cameras is drawing attention to its counter-drone and thermal-optics business. Bulls see room for recurring demand and further defense orders, while skeptics want earnings and revenue to confirm the growth story; broad market and defense-sector weakness have also weighed on the shares.

Kratos Defense & Security Solutions, Inc. engages in the provision of mission critical products, services and solutions for United States national security priorities. It operates through the Kratos Government Solutions (KGS) and Unmanned Systems (US) segments. The KGS segment consists of an aggregation of KGS operating segments, including microwave electronic products, space, satellite and cyber, training solutions. The US segment refers to the unmanned aerial, unmanned ground, unmanned seaborne and related command, control and communications system businesses. The company was founded on December 19, 1994, and is headquartered in Round Rock, TX.

Kratos Defense & Security Solutions Inc

KTOS is drawing attention for its steep, prolonged selloff and repeated tests of key support, with traders debating whether the weakness reflects valuation concerns, insider selling and a broader defense-sector pullbackor an oversold buying opportunity. Optimists point to contract wins, growth prospects and analyst upgrades, while skeptics say positive developments have not reversed the downtrend ahead of upcoming earnings.

Cosmos (ATOM) is a cryptocurrency . Cosmos has a current supply of 538,743,080.257876. The last known price of Cosmos is 1.54934617 USD and is up 3.36 over the last 24 hours. It is currently trading on 999 active market(s) with $34,414,170.84 traded over the last 24 hours. More information can be found at https://cosmos.network/.

Cosmos

Cosmos ATOM is drawing attention amid persistent price weakness, with holders highlighting staking rewards and hoping for renewed adoption and an altcoin rebound. Bearish traders counter that token inflation and a fading ecosystem are weighing on the outlook; institutional-adoption and regulatory catalysts remain largely speculative in the discussion.

Sky (SKY) is a cryptocurrency and operates on the Ethereum platform. Sky has a current supply of 23,452,431,915.60596656 with 23,422,827,962.33348843 in circulation. The last known price of Sky is 0.06706993 USD and is up 0.91 over the last 24 hours. It is currently trading on 257 active market(s) with $49,629,100.47 traded over the last 24 hours. More information can be found at https://sky.money/.

Skycoin

Galaxy Digitals adoption of Skys yield-bearing stablecoin for its treasury and lending collateral, alongside a reported purchase of SKY, is driving discussion of growing institutional interest in the Sky ecosystem. Traders are watching for a breakout, while others see the recent pullback as a warning and question whether the rally can hold.

Direxion Shares ETF Trust - Direxion Daily GOOGL Bull 2X ETF

Direxion Daily GOOGL Bull 2X Shares ETF

Alphabets sharp post-earnings selloff is driving attention to GGLL, with many traders buying the dip for a rebound while others warn that market weakness and deteriorating technicals could bring further declines.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

12 Health Care Stocks Moving In Friday's Intraday Session

Gainers

Immuron (NASDAQ:IMRN) shares moved upwards by 48.2% to $1.65 during Friday's regular session. The market value of their outstanding shares is at $8.9 million.
bioAffinity Technologies (NASDAQ:BIAF) sharesread more...

Digestive Health Expansion Sends This Microcap Soaring

Digestive health has become a sizable consumer-health category as patients increasingly look beyond short-term symptom relief toward products designed for regular use. In the U.S. alone, the digestive and gut health supplement market is estimated at $4.16 billion by one industry estimate, creating a broad commercial opportunity for companies that can carve out focused niches within the category.Shares of Immuron Limited (NASDAQ: IMRN) are surging Friday after the Australian biopharmaceutical company announced an exclusive U.S. distribution agreement with Sweden-based Calmino group AB for ...

IMRN Stock Skyrockets 60%, Heads For Best Day In Over 2 Years – What’s Driving The Super Rally Today? 

Equity

Immuron signed an agreement with Sweden’s Calmino Group to distribute digestive-health product Proibs in the U.S

12 Health Care Stocks Moving In Friday's Pre-Market Session

Gainers

Immuron (NASDAQ:IMRN) stock increased by 64.9% to $1.83 during Friday's pre-market session. The company's market cap stands at $8.9 million.
Akanda (NASDAQ:AKAN) shares increased by 27.52% to $4.68.read more...

Immuron To Launch PROIBS In U.S. After Australia Debut; Pre-market Shares Up

(RTTNews) - Australian biopharmaceutical company Immuron Ltd. (IMC.AX, IMRN), announced on Friday that it has signed an exclusive distribution deal with Sweden's Calmino group AB to launch its digestive health product PROIBS in the United States, following its rollout in Australi...

Immuron Takes PROIBS to America, as New U.S. Growth Engine Could be Taking Shape

Immuron (NASDAQ:IMRN) is adding another potentially important piece to its U.S. commercial strategy, announcing an exclusive distribution agreement with Sweden’s Calmino group AB to bring PROIBS to the American market. The move expands Immuron’s digestive-health portfolio beyond Travelan and gives the company another commercial product aimed at a large and recurring consumer-health need: the symptoms associated with irritable bowel syndrome. Importantly, this is not a molecule sitting years away from commercialization. PROIBS has already been sold in Sweden for more than a decade and, according to Calmino, was the best-selling IBS product in Swedish pharmacies during 2025, based on IQVIA sales data.

Immuron Stock Rallies After CEO Dismisses US Pharma Tariff Impact, Provides Positive Pipeline Updates

CEO Steven Lydeamore stated that while Travelan is imported into the U.S. from Australia, it is not a pharmaceutical product but a dietary supplement, and is therefore not expected to be impacted by U.S. pharmaceutical tariffs. 


Immuron Ltd. is a biopharmaceutical company, which focuses on the development and commercialization of a novel class of specifically targeted polyclonal antibodies. It operates through the Hyper-immune Products and Research and Development (R&D) segments. The Hyper-immune Products segment includes income and expenses directly attributable to Travelan and Protectyn activities. The Research and Development segment refers to the group’s R&D projects performed in Australia and United States. The company was founded on January 13, 1994, and is headquartered in Blackburn, Australia.

Immuron Limited - ADR

Neutral Sentiment

<ul class="summary-bullets"><li>Proibs is a medical device used to relieve abdominal pain, bloating, diarrhea and constipation.</li><li>The company said it is targeting a portion of the U.S. digestive and gut-health supplement market, which it estimates at $4.16 billion.</li><li>In a study involving 1,003 users, 94% said Proibs was helpful, and 91% reported an improvement in daily life.</li></ul>Shares of Immuron (IMRN) surged more than 60% on Friday after the biopharmaceutical company signed an exclusive agreement with Sweden’s Calmino Group to distribute digestive-health product Proibs in the U.S.<a href="https://stocktwits.com/symbol/IMRN">IMRN stock</a> hit its highest levels since November 2025 and is on track to clock its biggest single-day gains since March 2024.<h2 class="st-heading-2">IMRN To Tap Into $4.2B Gut Health Market</h2>Proibs is a medical device used to relieve abdominal pain, bloating, diarrhea, and constipation. In a study conducted by Calmino involving 1,003 users, 94% said Proibs was helpful, 91% reported an improvement in daily life, and 98% said they would recommend the product.The company said it is targeting a portion of the U.S. digestive and gut-health supplement market, which it estimates at $4.16 billion.The deal expands Immuron’s commercial portfolio beyond Travelan, an over-the-counter tablet to prevent diarrhea.<h2 class="st-heading-2">IMM-529 Is Immuron’s Next Big Bet</h2>Immuron is also advancing IMM-529, its experimental oral treatment for recurrent Clostridioides difficile infection, which can cause severe diarrhea. Last November, the U.S. Food and Drug Administration (FDA) approved the company’s Investigational New Drug application, allowing IMM-529 to move toward a Phase 2 trial.Healthcare consultancy firm Lumanity estimates IMM-529’s peak U.S. sales of $400 million.<h2 class="st-heading-2">Retail Flags ‘Insane’ Volumes</h2>Retail sentiment surrounding IMRN on Stocktwits flipped to ‘extremely bullish’ from ‘neutral,’ amid ‘extremely high’ message volumes.One user said the stock could climb to $5, highlighting the “insane volume.”<stembedurl>https://stocktwits.com/luckylunatic/message/663637534</stembedurl>More than 80 million shares changed hands, far exceeding the daily average of around 16,000, according to Stocktwits data.Another user highlighted $1.95 as key resistance.<stembedurl>https://stocktwits.com/SmartMoneyTradez/message/663632669</stembedurl>The stock has gained around 135% so far this year.Also read: <a href="https://stocktwits.com/news-articles/markets/equity/planet-labs-is-on-a-roll-in-defense-and-intelligence-says-craig-hallum-why-did-the-firm-shave-its-target-by-over-28/cZsD38LRJwC">Planet Labs Is ‘On A Roll’ In Defense And Intelligence, Says Craig-Hallum — Why Did The Firm Shave Its Target By Over 28%?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Stock market data with uptrend vector | Illustration Source: Getty Images

IMMURON Ltd/S ADR

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Stocktwits

Stocktwits Polls

$IMRN anyone else seen anything similar to this before where BNY Mellon now controls 45.7% of all shares?  Rare to see increasing concentrated ownership like this in a small cap?

Psychedelic Viking

$IMRN by now you have heard of the mysterious pneumonia death caused in a russian lab. Who do you could profit greatly from the antidote? IMM-529

Cusco

$IMRN has its CEO Steven Lydeamore speaking virtually at the Emerging Growth Conference on Oct 28.

jorge .miguel

$IMRN 

Immuron Limited has announced that Chief Executive Officer Steven Lydeamore will deliver a virtual presentation at the Emerging Growth Conference on Wednesday, October 28, 2026.
During the live interactive event, the CEO is expected to provide key corporate updates to global investors on Kalkine Media regarding Immuron's current commercial assets and clinical trial pipeline:
• Commercial Growth: Updates on expanding their flagship product Travelan® (for travelers' diarrhea) and details surrounding the recent exclusive U.S. distribution contract for ProIBS® (for Irritable Bowel Syndrome), which officially starts its contractual revenue phase on November 1, 2026.

Leslie S

$IMRN hmmm $LLY once had a distribution deal with Calmino for the Proibs product this was back in 2021.

Meanwhile, some large pharmaceutical companies like $BDX are investing in US in exchange for tariff relief.

IMRN has a recent US distribution deal. Other interesting news, $WMT Sam’s Club is now selling boneless top sirloin imported from Australia; it’s taste and tenderness was like eating filet mignon

Feed

News

Sentiment

Fundamentals

Info

IMRN IMMURON Ltd/S ADR

Fundamentals

Latest IMRN News